These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24745679)

  • 21. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
    Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
    Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
    Tanaka H; Iwato K; Asou H; Kimura A
    Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 27. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
    Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
    Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
    [No Abstract]   [Full Text] [Related]  

  • 29. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Systemic mastocytosis].
    Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
    Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
    Helbig G; Stella-Hołowiecka B; Hołowiecki J
    Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib-responsive hypereosinophilic syndrome.
    Robyn J
    Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
    Winter L; Zellweger MJ; Bremerich J
    Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
    Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.